Company: GHRS
Filing Date: 2025-02-05
Form Type: 424B5
Source: 0001140361-25-003183
Chunk: 7

Company: GH Research PLC
Filing Date: 2025-02-05
Form: 424B5
Chunk 7
---
 $9.59 per share; and |

| • | 427,256 additional ordinary shares reserved for future issuance under our Share Option Plan as of September 30, 2024. |

Additionally, on November 24, 2024, our Board of Directors approved an amendment to our Share Option Plan to increase the amount of ordinary shares that may be issued pursuant to future option grants under such plan by 999,970 shares, and in connection therewith, during the quarter ended December 31, 2024, we granted additional options to purchase 1,135,000 ordinary shares. Unless otherwise indicated, all information contained in this prospectus supplement assumes no exercise by the underwriters of their option to purchase up to an additional 1,500,000 ordinary shares from us.

S-7

TABLE OF CONTENTS

RISK FACTORS Before investing in our ordinary shares you should carefully consider the risks and uncertainties discussed below and under the caption “Item 3. Key Information — D. Risk Factors” in our 2023 Annual Report, which is incorporated by reference in this prospectus supplement, as well as in the accompanying prospectus and in the other documents incorporated by reference in this prospectus supplement or the accompanying prospectus, including the Current Report on Form 6-K filed on February 3, 2025. For a description of those reports and documents, and information about where you can find them, please see “Where You Can Find More Information” and “Incorporation of Certain Documents by Reference.” Additional risks not presently known or that we presently consider to be not material could subsequently materially and adversely affect our financial condition, results of operations, business and prospects. Risks Related to the Offering and Ownership of Our Ordinary Shares The market price of our ordinary shares has historically been, and in the future may continue to be, volatile and may fluctuate due to factors beyond our control, and you could lose all or part of your investment. The price of the securities of publicly traded emerging pharmaceutical and drug discovery and development companies has been highly volatile and is likely to remain highly volatile in the future. In the past, we have experienced such volatility in the price of our ordinary shares. The market price of our ordinary shares could be subject to wide fluctuations in response to many risk factors, some of which are beyond our control, including the following:

| • | positive or negative results of testing and clinical trials by us, strategic partners or competitors; |

| • | a failure to lift, or significant delay in lifting